Introduction {#s1}
============

Prostate cancer (PCa) is the most commonly diagnosed malignant tumor and the second leading cause of cancer mortality in Western men. In 2012, 28170 people died of this malignancy and an estimated 241740 new cases of PCa were expected to be diagnosed in the U.S. [@pone.0085609-Siegel1]. Epidemiological studies have established that PCa morbidity in Asians is much lower [@pone.0085609-Quinn1]. However, in China, as the westernized lifestyle becomes more common, the occurrence of PCa has increased appreciably in recent years [@pone.0085609-McCracken1]. Age, race/ethnicity, genetic background, environmental factors and sex steroid hormone levels are thought to be associated with risk of PCa [@pone.0085609-Bostwick1]. Although many people are exposed to these risk factors, only a few individuals develop PCa in their lifetimes, suggesting that genetic variation may contribute to prostate carcinogenesis [@pone.0085609-Dianat1]. Improving results with the candidate gene approach have led to its growing acceptance as a potentially useful method for investigating genetic risk factors for PCa among Chinese.

Insulin-like growth factors (IGFs) are a large family of insulin-related peptides that include *IGF-I* and *IGF-II* as well as their cell surface receptors (*IGF-IR* and *IGF-IIR)*, insulin-like growth factors binding proteins (*IGFBP-1-6*), IGFBP proteases and several other IGFBP-interacting molecules [@pone.0085609-Jones1], which all regulate cell proliferation, differentiation and apoptosis [@pone.0085609-Khandwala1]. The IGFs are bound to several proteins that are involved in different pathways that control cell proliferation and survival including Ras/Raf/mitogenactivated protein kinase (MAPK) [@pone.0085609-Maroni1], phosphatidylinositol 3-kinase (PI3K)/Akt [@pone.0085609-McIntosh1] and nuclear factor-κB (NF-κB) [@pone.0085609-Vivanco1]. *IGF-I* is located on chromosome 12 and is a 70 amino acid peptide. *IGFBP-3* is located on chromosome 7 and is a 264 amino acid peptide. Both of *IGF-1* and *IGFBP-3* are primarily produced by the liver [@pone.0085609-Pollak1]. The majority of circulating *IGF-I* binds to the main IGF binding protein (*IGFBP-3*); at the same time the *IGFBP-3* regulates the biological activity of *IGF-I*.

Studies have shown that *IGF-I* plays an important role in mitogenesis and antiapoptosis [@pone.0085609-Khandwala1], whereas *IGFBP-3* may be antiproliferative and proapoptotic through growth inhibition [@pone.0085609-Firth1]. Epidemiological studies have confirmed that genetic variations of *IGF-I* and *IGFBP-3* are associated with an increased risk of common cancers, including PCa, colorectal cancer, lung cancer and breast cancer [@pone.0085609-Chan1], [@pone.0085609-Hankinson1], [@pone.0085609-Ma1], [@pone.0085609-Yu1].

Given the important role of *IGF-I* and *IGFBP-3* in tumors, we hypothesized that genetic variants of these two genes could have an effect on the risk of PCa. In the present study, five single nucleotide polymorphisms (SNPs) in *IGF-I* (rs6214, rs6218, rs35767, rs5742612, rs5742714) and four SNPs in *IGFBP-3* (rs2132572, rs2854744, rs2854746, rs9282734) were selected and their association with PCa risk in the Chinese population was evaluated.

Materials and Methods {#s2}
=====================

Study Population {#s2a}
----------------

Between December 2003 and March 2010, 664 untreated PCa patients and 702 control subjects were recruited from the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. All patients were diagnosed via histopathology; control subjects were recruited from among those seeking routine outpatient care and were screened via digital rectal examination (DRE) and presumed to be cancer-free. All subjects were unrelated, ethnic, southern Han Chinese. Each participant was interviewed, in person, by trained interviewers. Detailed information and epidemiological risk factors were collected including age, tobacco use, alcohol use, and family history of cancer. In the present study, individuals who had smoked daily for more than one year were defined as smokers; all others were defined as nonsmokers. Cumulative smoking dose is indicated by Pack-years of smoking (cigarettes per day/20) × years smoked. Individuals who had used alcohol at least three times per week for more than six months were defined as drinkers and the others were defined as non-drinkers. Family history of cancer was defined as any cancer in first-degree relatives (parents, siblings, or children). Disease stage was determined by pathologic findings, pelvic computed tomography, magnetic resonance imaging and radio-nucleotide bone scans. The tumor stage was determined using the international tumor-node-metastasis (TNM) classification and graded according to WHO guidelines. The disease stage was divided into localized and advanced cancer based on the TNM classification system promulgated by the American Joint Committee on Cancer. Localized PCa are those that can be detected clinically or felt (palpated) upon examination, but that have not spread outside the prostate (T~1--2~N~0~M~0~). Advanced PCas are those that have spread outside the prostate (T~3--4~N~x~M~x~, T~x~N~1~M~x~ or T~x~N~x~M~1~). Serum PSA values were estimated by pathologists working at the hospital and divided into two groups PSA \>20 ng/ml and PSA ≤20 ng/ml, based on the EAU Guidelines on PCa and on D'Amico's Risk-Based management of PCa. Each subject donated 5 ml of blood for genomic DNA extraction after having given their written informed consent. The institutional review board of Nanjing Medical University approved the research protocol.

SNP Selection {#s2b}
-------------

Based on HapMap data (<http://hapmap.ncbi.nlm.nih.gov/>) and PubMed data (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), we selected 4 SNPs in *IGF-I* (rs6214, rs6217, rs6218, rs35767) and 2 SNPs in *IGFBP-3* (rs2132572, rs9282734). Minor allele frequency (MAF) of all of these genes is more than 5% in the Han Chinese population. Considering a complete linkage disequilibrium (r^2^ = 1) with rs6217, only rs6218 was selected for genotyping. Finally we included one SNP in *IGF-I* (rs5742714) and two SNPs in *IGFBP-3* (rs2854744, rs2854746), which were recently found to be significantly associated with some malignancies in the Chinese population [@pone.0085609-Zhang1], [@pone.0085609-Deming1], [@pone.0085609-Qian1].

Genotyping {#s2c}
----------

Genomic DNA was extracted from anti-coagulated peripheral blood leukocytes by proteinase K digestion and phenol/chloroform extraction. Genotyping was performed with the TaqMan SNP Genotyping Assay. The PCR reactions were carried out in a total volume of 5 µL containing TaqMan Universal Master Mix, 80X SNP Genotyping AssayMix, Dnase-free water and 10-ng genomic DNA. The PCR conditions were 2 min at 50°C, 10 min at 95°C, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. The 384-well ABI 7900HT Real Time PCR System (Applied Biosystems, Foster City, CA, USA) was used for the genotyping assay, according to the manufacturer's instructions and the Sequence Detection Systems software (SDS 2.3; Applied Biosystems) was used to automatically collect and analyze the data and to generate the genotype calls. Four negative controls were included in each plate to ensure accuracy of the genotyping. Two people performed genotyping independently, in a blinded manner, to ensure quality control. Approximately 5% of the samples were randomly selected for repeated genotyping and the results were 100% concordant.

Statistical Analysis {#s2d}
--------------------

Pearson's chi-square (χ^2^) test was used to analyze differences in frequency distributions of demographic variables, pack-years of smoking, smoking status, alcohol use, family history of cancer and genotype frequencies between PCa cases and controls. Using an unconditional logistic regression, we estimated the association between the polymorphisms and risk of PCa by odds ratios (ORs) and their 95% confidence intervals (CIs). All ORs were adjusted for age, cigarette smoking, drinking status and family history. All statistical analyses were two-sided and performed with Statistics Analysis System software (Version 9.1.3; SAS Institute, Inc., Cary, NC, USA) and *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the Study Population {#s3a}
---------------------------------------

The demographic characteristics and clinical information of PCa cases and controls are outlined in [Table 1](#pone-0085609-t001){ref-type="table"}. There were no significant differences between the PCa cases and controls in the terms of age (*P*  = 0.76). However, the frequency of smokers and drinkers was higher in the PCa case group than in the control group (58.0% versus 50.4%, *P*\<0.01; 29.7% versus 24.5%, *P*  = 0.03, respectively). Moreover, there were a significantly higher proportion of PCa cases with a positive family history of cancer when compared with controls (*P*\<0.01). Among PCa cases, 389 (58.6%) patients had a PSA level \<20 ng/ml. The number and percent of subjects showing a Gleason score \<7,  = 7 and \>7 was 225 (33.9%), 220 (33.1%) and 219 (33.0%), respectively. Furthermore, 393 (59.2%) patients were in the localized stage and 271 (40.8%) patients were in the advanced stage.

10.1371/journal.pone.0085609.t001

###### Distribution of selected characteristics among the PCa cases and control subjects.

![](pone.0085609.t001){#pone-0085609-t001-1}

  Characteristic              Cases (n = 664)   Controls (n = 702)   *P* [\*](#nt101){ref-type="table-fn"}         
  -------------------------- ----------------- -------------------- --------------------------------------- ------ ---------
  Age (years)(Mean ± SD)         71.5±8.0            71.3±7.4                        0.762                         
  ≤71                               306                46.1                           346                    49.3    0.216
  \>71                              358                53.9                           356                    50.7  
  Smoking status                                                                                                     0.005
  Nonsmoker                         279                42.0                           348                    49.6  
  Smoker                            385                58.0                           354                    50.4  
  Pack-years of smoking                                                                                             \<0.001
  0                                 279                42.0                           348                    49.5  
  0--22.5                           165                24.9                           174                    29.8  
  \>22.5                            220                33.1                           181                    20.7  
  Drinking status                                                                                                    0.031
  No                                467                70.3                           530                    75.5  
  Yes                               197                29.7                           172                    24.5  
  Family history of cancer                                                                                          \<0.001
  No                                538                81.0                           647                    92.2  
  Yes                               126                19.0                           55                     7.8   
  Clinical stage                                                                                                   
  Localized                         393                59.2                                                        
  Advanced                          271                40.8                                                        
  Gleason score                                                                                                    
  \<7                               225                33.9                                                        
   = 7                              220                33.1                                                        
  \>7                               219                33.0                                                        
  PSA(ng/ml)                                                                                                       
  ≤20                               389                58.6                                                        
  \>20                              275                41.4                                                        

\*T-test for age distributions between the cases and controls; two-sided χ^2^ test for others selected variables between the cases and controls.

Distribution of the IGF-I and IGFBP-3 Genotype between the Cases and Controls {#s3b}
-----------------------------------------------------------------------------

Genotype and allele frequencies of the nine polymorphisms among the PCa patients and control subjects, and their associations with risk of PCa, are shown in [Table 2](#pone-0085609-t002){ref-type="table"}. The observed genotype frequencies of the polymorphisms in the control group were consistent with Hardy-Weinberg equilibrium (HWE) (*P*\>0.05). As shown in [Table 2](#pone-0085609-t002){ref-type="table"}, we observed significant differences in the distribution of the genotype and allele frequencies of rs6218, rs35767 and rs5742612 between the PCa patients and control subjects (*P*\<0.05). For the rs6218 polymorphism, the frequencies of the TT, TC and CC genotypes were 50.1%, 43.7% and 6.2% among PCa cases and 58.3%, 35.0% and 6.7% among controls, respectively (*P*\<0.01). The frequencies of the CC, CT, and TT genotypes for rs35767 were 36.5%, 48.6% and 14.9% among PCa cases and 43.3%, 46.6% and 10.1% among controls, respectively (*P*\<0.01). Similarly, the frequencies of the TT, TC and CC genotypes for rs5742612 were 44.1%, 44.0% and 11.9% among PCa cases and 51.4%, 39.3% and 9.3%, among controls, respectively (*P*  = 0.02). Based on logistic regression analysis, when using the rs6218 TT genotype as the reference, the TC/CC genotype of the SNP rs6218 was associated with a significantly increased risk of PCa compared with the TT genotype (adjusted OR  =  1.37, 95% CI  = 1.10--1.70). Similarly, a significantly increased risk of PCa was found in the combined genotype rs35767 CT/TT compared with the CC genotype (adjusted OR  = 1.35, 95% CI  = 1.08--1.69). For the SNP rs5742612, the TC (adjusted OR  = 1.30, 95% CI  = 1.03--1.64), CC (adjusted OR  = 1.44, 95% CI  = 0.99--2.09) and TC/CC (adjusted OR  = 1.33, 95% CI  = 1.07--1.66) genotypes were associated with a statistically elevated risk of PCa when compared with the TT genotype.

10.1371/journal.pone.0085609.t002

###### SNPs in the IGF-I and IGFBP-3 associated with the prostate cancer risk.

![](pone.0085609.t002){#pone-0085609-t002-2}

  Polymorphisms        Cases (n = 664)   Controls (n = 702)   P [\*](#nt102){ref-type="table-fn"}   Adjusted OR (95% CI)[†](#nt103){ref-type="table-fn"}          
  ------------------- ----------------- -------------------- ------------------------------------- ------------------------------------------------------ ------- ------------------
  IGF-Irs6214                                                                                                                                                     
  GG                         178                26.8                          210                                           29.9                           0.353   1.00(reference)
  GA                         322                48.5                          336                                           47.9                                   1.13(0.87--1.47)
  AA                         164                24.7                          156                                           22.2                                   1.25(0.92--1.70)
  IGF-Irs6218                                                                                                                                                     
  TT                         333                50.1                          409                                           58.3                           0.005   1.00(reference)
  TC                         290                43.7                          246                                           35.0                           0.001   1.42(1.13--1.79)
  CC                         41                 6.2                           47                                            6.7                            0.760   1.05(0.67--1.66)
  TC/CC                      331                49.9                          293                                           41.7                           0.003   1.37(1.10--1.70)
  T                          956                72.0                         1064                                           75.8                           0.023   1.00(reference)
  C                          372                28.0                          340                                           24.2                                   1.28(1.03--1.61)
  IGF-Irs35767                                                                                                                                                    
  CC                         242                36.5                          304                                           43.3                           0.005   1.00(reference)
  CT                         323                48.6                          327                                           46.6                           0.063   1.27(1.00--1.60)
  TT                         99                 14.9                          71                                            10.1                           0.002   1.71(1.20--2.44)
  CT/TT                      422                63.5                          398                                           56.7                           0.010   1.35(1.08--1.69)
  C                          807                60.7                          935                                           66.6                           0.002   1.00(reference)
  T                          521                39.3                          469                                           33.4                                   1.33(1.04--1.64)
  IGF-Irs5742612                                                                                                                                                  
  TT                         293                44.1                          361                                           51.4                           0.020   1.00(reference)
  TC                         292                44.0                          276                                           39.3                           0.021   1.30(1.03--1.64)
  CC                         79                 11.9                          65                                            9.3                            0.029   1.44(0.99--2.09)
  TC/CC                      371                55.9                          341                                           48.6                           0.007   1.33(1.07--1.66)
  T                          878                66.1                          998                                           71.1                           0.005   1.00(reference)
  C                          450                33.9                          406                                           28.9                                   1.34(1.09--1.61)
  IGF-Irs5742714                                                                                                                                                  
  GG                         448                67.5                          492                                           70.1                           0.367   1.00(reference)
  GC                         195                29.4                          195                                           27.8                           0.437   1.08(0.85--1.37)
  CC                         21                 3.1                           15                                            2.1                            0.208   1.52(0.76--3.02)
  IGFBP-3 rs2132572                                                                                                                                               
  GG                         422                63.6                          447                                           63.7                           0.820   1.00(reference)
  GA                         210                31.6                          226                                           32.2                           0.893   0.97(0.77--1.23)
  AA                         32                 4.8                           29                                            4.1                            0.556   1.17(0.68--2.00)
  IGFBP-3 rs2854744                                                                                                                                               
  CC                         408                61.4                          424                                           60.4                           0.904   1.00(reference)
  CA                         225                33.9                          246                                           35.0                           0.660   0.95(0.76--1.20)
  AA                         31                 4.7                           32                                            4.6                            0.980   1.05(0.62--1.78)
  IGFBP-3 rs2854746                                                                                                                                               
  CC                         398                59.9                          420                                           59.8                           0.999   1.00(reference)
  CG                         228                34.4                          242                                           34.5                           0.960   0.99(0.79--1.25)
  GG                         38                 5.7                           40                                            5.7                            0.992   0.99(0.62--1.61)
  IGFBP-3 rs282734                                                                                                                                                
  AA                         598                90.0                          636                                           90.6                           0.724   1.00(reference)
  AC                         61                 9.2                           63                                            9.0                            0.876   1.03(0.71--1.50)
  CC                          5                 0.8                            3                                            0.4                            0.428   1.71(0.40--7.36)

\*Two-sided χ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

Adjusted for age, smoking status, drinking status and family history of cancer in logistic regression model; 95% CI: 95% confidence interval.

Combined Analysis between the Three Polymorphisms and PCa Susceptibility {#s3c}
------------------------------------------------------------------------

Because all three SNPs (rs6218, rs35767 and rs5742612) appeared to be associated with an increased risk of PCa, we combined them, based on the number of the risk alleles, and evaluated the potential interactions of the polymorphisms on the risk of PCa. As listed in [Table 3](#pone-0085609-t003){ref-type="table"}, statistical significance was observed in the combined analysis of risk alleles (*P*\<0.01). Furthermore, we classified the risk alleles into two groups according to the number of risk alleles. We found that the risk of PCa was significantly increased in subjects that carried 2--6 risk alleles compared to those carrying 0--1 risk allele(s) (OR  = 1.30, 95%CI  = 1.05--1.62, *P*  = 0.01).

10.1371/journal.pone.0085609.t003

###### Stratification analyses between *IGF-I* and *IGFBP-3* genotypes and risk of PCa in cases and controls.

![](pone.0085609.t003){#pone-0085609-t003-3}

                                                           Cases (n = 664)   Controls (n = 702)   *P* [\*](#nt104){ref-type="table-fn"}   Adjusted OR (95% CI)[†](#nt105){ref-type="table-fn"}              
  ------------------------------------------------------- ----------------- -------------------- --------------------------------------- ------------------------------------------------------ ----------- ------------------
  Number ofrisk alleles[‡](#nt106){ref-type="table-fn"}                                                                                                                                                     
  0                                                              213                32.3                           266                                            37.9                           **0.004**   1.00(reference)
  1                                                              74                 11.1                           85                                             22.1                             0.649     1.13(0.78--1.63)
  2                                                              55                 8.3                            86                                             12.3                             0.250     0.79(0.53--1.17)
  3                                                              221                33.3                           185                                            26.4                           **0.003**   1.51(1.15--1.99)
  4                                                              42                 6.3                            28                                             4.0                            **0.015**   1.74(1.03--2.95)
  5                                                              26                 3.9                            21                                             3.0                              0.154     1.57(0.85--1.92)
  6                                                              33                 5.0                            31                                             4.4                              0.284     1.30(0.76--2.33)
  Recombinedgroups                                                                                                                                                                                          
  0--1                                                           287                43.2                           351                                            50.0                           **0.012**   1.00(reference)
  2--6                                                           377                56.7                           351                                            50.0                                       1.30(1.05--1.62)

\*Two-sided χ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

Adjusted for age, smoking status, drinking status and family history of cancer in logistic regression model; 95% CI: 95% confidence interval.

The 0--6 represents the numbers of risk alleles within the combined genotypes; the risk alleles used for the calculation were the rs6218C, rs35767T and rs5742612C alleles.

Stratification Analysis between the Combined Genotypes and Risk of PCa {#s3d}
----------------------------------------------------------------------

The effect on PCa risk of the combined alleles of the three polymorphisms was then evaluated by age, smoking status, pack-years of smoking, drinking status and family history of cancer. As shown in [Table 4](#pone-0085609-t004){ref-type="table"} **,** we found that the association appeared stronger in the following subgroups: those who were more than 71 years of age (OR  = 1.41, 95%CI  = 1.05--1.91, *P*  = 0.02), nonsmokers (OR  = 1.68, 95%CI  = 1.21--2.32, *P*\<0.01), nondrinkers (OR  = 1.32, 95%CI  = 1.02--1.71, *P*\<0.01) and those with a negative for family history of cancer (OR  = 1.28, 95%CI  = 1.02--1.61, *P*  = 0.02). We further investigated the association between the combined risk alleles and clinicopathological characteristics of PCa ([Table 5](#pone-0085609-t005){ref-type="table"}). No statistical evidence was found for any interaction between the combined genotypes and progression of PCa.

10.1371/journal.pone.0085609.t004

###### Stratification analysis of the variant numbers of genotypes by selected variables in PCa patients and controls.

![](pone.0085609.t004){#pone-0085609-t004-4}

  Variables                  Cases (n = 664)   Controls (n = 702)   *P* [\*](#nt107){ref-type="table-fn"}   Adjusted OR (95% CI)[†](#nt108){ref-type="table-fn"}                                        
  ------------------------- ----------------- -------------------- --------------------------------------- ------------------------------------------------------ ----- ------ ----- ------ ----------- ------------------
  Total                            287                43.2                           377                                            56.8                           351    50    351    50    **0.012**   1.30(1.05--1.62)
  Age (years)                                                                                                                                                                                           
  ≤71                              140                45.8                           166                                            54.2                           174   50.3   172   49.7     0.247     1.21(0.88--1.67)
  \>71                             147                41.1                           211                                            58.9                           211   49.7   179   50.3   **0.020**   1.41(1.05--1.91)
  Smoking status                                                                                                                                                                                        
  Nonsmoker                        118                42.3                           161                                            57.7                           190   54.6   158   45.4   **0.002**   1.68(1.21--2.32)
  Smoker                           169                43.9                           216                                            56.1                           161   45.5   193   54.5     0.665     1.05(0.78--1.41)
  Pack-years of smoking                                                                                                                                                                                 
  0                                118                42.3                           161                                            57.7                           190   54.6   158   45.4   **0.002**   1.68(1.21--2.32)
  0--22.5                          73                 44.2                           92                                             55.8                           99    47.4   110   52.6     0.547     1.15(0.76--1.74)
  \>22.5                           96                 43.6                           124                                            56.4                           62    42.7   83    57.2     0.869     0.95(0.61--1.46)
  Drinking status                                                                                                                                                                                       
  No                               203                43.5                           264                                            56.5                           268   50.6   262   49.4   **0.025**   1.32(1.02--1.71)
  Yes                              84                 42.6                           113                                            57.4                           83    48.3   89    51.7     0.280     1.25(0.82--1.89)
  Familyhistory of cancer                                                                                                                                                                               
  No                               231                42.9                           307                                            57.1                           321   49.6   326   50.4   **0.022**   1.28(1.02--1.61)
  Yes                              56                 44.4                           70                                             55.6                           30    54.6   25    45.4     0.211     1.46(0.76--2.81)

\*Two-sided χ^2^ test for number of risk alleles in cases and controls.

Adjusted for age, pack-years of smoking, drinking status, and family history of cancer in logistic regression model; 95% CI: 95% confidence.

10.1371/journal.pone.0085609.t005

###### Association between *IGF-I* and *IGFBP-3* polymorphism and clinicopathologic characteristics of PCa.

![](pone.0085609.t005){#pone-0085609-t005-5}

  Variables        Risk allele   *P*    Adjusted OR (95% CI)[\*](#nt109){ref-type="table-fn"}2--6 versus 0--1                 
  --------------- ------------- ------ ----------------------------------------------------------------------- ------ ------- ------------------
  Clinicalstage                                                                                                               
  Localized            170       43.3                                    223                                    56.7   0.983   1.00(reference)
  Advanced             117       43.2                                    154                                    56.8           1.00(0.73--1.37)
  Gleasonscore                                                                                                                
  \<7                  101       44.9                                    124                                    55.1   0.171   1.00(reference)
  7                    84        38.2                                    136                                    61.8           0.77(0.53--1.14)
  \>7                  102       46.6                                    117                                    53.4           1.05(0.87--1.26)
  PSA(ng/ml)                                                                                                                  
  ≤20                  174       44.7                                    215                                    55.3   0.351   1.00(reference)
  \>20                 113       41.1                                    162                                    58.9           0.85(0.62--1.16)

\*Adjusted for age, smoking status, drinking status, and family history of cancer in logistic regression model; 95% CI: 95% confidence interval; OR: odds ratio.

Discussion {#s4}
==========

Substantial epidemiologic and experimental evidence, both *in vivo* and *in vitro,* have implicated the IGF pathway as playing a role in prostate carcinogenesis and progression, including cellular metabolism, differentiation, proliferation, transformation, anti-apoptosis, angiogenesis, bone metastases and androgen-independent progression [@pone.0085609-Khandwala1], [@pone.0085609-Yu2], [@pone.0085609-Peehl1]. *IGF-I* can be synthesized and exported by almost all human cells including the prostate tissue [@pone.0085609-Rosen1]. As a potent mitogen, *IGF-I* exerts the mitogenic action of both normal and cancer cells by elevating DNA synthesis, stimulating the cell cycle progression and inhibiting apoptosis [@pone.0085609-Qu1]. *IGFBP-3,* the most abundant form of IGFBP, binds \>90% of *IGF-I*, thus determining the bioavailability of *IGF-I* [@pone.0085609-Samani1]. *IGF-I* and *IGFBP-3* polymorphisms have been reported to be associated with the risk of PCa in many populations, including Caucasians, African Americans and Japanese [@pone.0085609-Cheng1]. Furthermore, many studies have demonstrated an increased risk of PCa with higher circulating concentrations of *IGF-I* or lower circulating concentrations of *IGFBP-3* [@pone.0085609-Chen1], [@pone.0085609-Stattin1]. Therefore, we examined whether *IGF-I* and *IGFBP-3* SNPs would affect the risk of PCa in the Chinese population.

In the present study, we assessed the association between nine *IGF-I* and *IGFBP-3* polymorphisms and PCa susceptibility and progression. We found that three SNPs in *IGF-I* (rs6218, rs35767 and rs5742612) were associated with an elevated risk of PCa and that the increased risk was significant among PCa patients that carried the rs6218 TC/CC, the rs35767 CT/TT or the rs5742612 TC/CC genotype. The presence of these risk alleles posed a considerable threat of PCa development in older subjects (\>71 years old), non-smokers, non-drinkers and those without a family history of PCa. However, we did not observe any statistical associations between the remaining SNPs and PCa risk.

Recently, the association between the *IGF-I* and *IGFBP-3* polymorphisms and the risk of various cancers, including PCa, has been clarified by many genetic approaches using single amino acid mutations and by molecular epidemiological studies [@pone.0085609-Zhang1], [@pone.0085609-Deming1], [@pone.0085609-Terry1], [@pone.0085609-Zecevic1], [@pone.0085609-Lin1], [@pone.0085609-McGrath1]. The conclusion regarding *IGF-I* SNPs in our study is supported by the results of previous studies. Additionally, our results indicated no discrepancy in the genotype distribution of the *IGFBP-3* polymorphisms when comparing PCa cases to controls. Fredrick et al. reported that the variation of the *IGFBP-3* polymorphism (rs2854744) had no association with the risk of PCa among Caucasians [@pone.0085609-Schumacher1]. Similarly, Mattias et al. suggested that rs2854744 was not associated with the incidence of PCa and survival in the Swedish population [@pone.0085609-Johansson1]. These results are in accordance with the conclusion of the present study. To our knowledge, this is the first study to evaluate the genetic association between the *IGF-I* and *IGFBP-3* polymorphisms and the risk of PCa in the Chinese population.

*IGF-I*, produced both by liver and locally on the prostate tissue, has effects on prostate carcinogenesis. Epidemiological studies have suggested that a high level of *IGF-I* may increase the risk of PCa in many races [@pone.0085609-Johansson1], [@pone.0085609-Darago1]. We noted that *IGF-I* levels have been shown to be significantly different between ethnic groups, and a similar result was found among the Chinese [@pone.0085609-Peng1]. Although the *IGF-I* level is regulated by many factors, about half of the inter-individual variability in serum *IGF-I* can be genetically determined [@pone.0085609-Harrela1]. Considering the relationship of the three *IGF-I* SNPs and PCa risk, we considered whether these genetic variations could be related to the regulation of *IGF-I*. More evidence and research is needed to clarify the association between the three polymorphisms and *IGF-I* level.

In this study, we observed that the rs6218C allele (1.28-fold), rs35767T allele (1.33-fold) and rs5742612C allele (1.34-fold) were associated with a significantly increased risk for PCa. Our results indicated that the rs6218C allele, rs35767T allele and rs5742612C allele were the risk alleles for PCa in the Chinese population. Analysis of the combined alleles was then done in order to obtain a comprehensive estimation of genetic susceptibility for the candidate genes. We found that individuals with joint genotypes containing 2--6 risk alleles had a distinctly higher risk of developing PCa than those whose joint genotypes contained 0--1 risk allele(s). Our results indicated a stronger effect of the alleles on PCa among individuals who were older than 71. This observation is supported by a retrospective study that found that link DNA damage accumulates with increasing age [@pone.0085609-Maslov1]. In addition, we found that the risk of PCa was more pronounced in nonsmokers and nondrinkers. We know that higher circulating concentrations of *IGF-I* may contribute to a higher risk of PCa and a previous study by Libby M *et al.* reported that circulating *IGF-I* was influenced by lifestyle factors [@pone.0085609-Morimoto1]. One explanation for the higher risk of PCa in nonsmokers and nondrinkers may be that environmental effects overwhelm the effects of genetics.

Some limitations of this study should be noted. First, the sample size was moderate, which limited the statistical power of combined analysis and stratification. Second, the lack of detailed information on cancer risk factors such as diet, physical activity and occupational exposure further limited evaluating the associations between environmental factors and PCa risk. Third, our study was a retrospective hospital-based study so the inherent selection bias could not be entirely excluded. In addition, considering the limitations of DRE, we might have had some misclassification of disease among control subjects. However, all genotype frequencies of the nine polymorphisms that occurred in PCa patients and in controls subjects in this study were in agreement with HWE, suggesting that the selection bias was unlikely to be substantial.

In conclusion, the present study provides evidence to elucidate the genetic effects of the *IGF-I* and *IGFBP-3* SNPs on the pathogenesis and progression of PCa. We found three polymorphisms in *IGF-I* (rs6218, rs35767 and rs5742612), and their combined alleles, that might elevate the risk of PCa in the Chinese population. Further epidemiological studies with larger sample size and more environmental and survival factors are needed in order to confirm our findings.
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